APR-246 + Pegylated Liposomal Doxorubicin Hydrochloride (PLD)
Phase 2Completed 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
High-grade Serous Ovarian Cancer
Conditions
High-grade Serous Ovarian Cancer
Trial Timeline
Jul 31, 2017 → Jul 10, 2019
NCT ID
NCT03268382About APR-246 + Pegylated Liposomal Doxorubicin Hydrochloride (PLD)
APR-246 + Pegylated Liposomal Doxorubicin Hydrochloride (PLD) is a phase 2 stage product being developed by Aprea Therapeutics for High-grade Serous Ovarian Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT03268382. Target conditions include High-grade Serous Ovarian Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03268382 | Phase 2 | Completed |
Competing Products
8 competing products in High-grade Serous Ovarian Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| azenosertib | Zentalis Pharmaceuticals | Phase 2 | 44 |
| Sepantronium Bromide | Cothera Bioscience | Phase 2 | 44 |
| Mirvetuximab Soravtansine | AbbVie | Phase 2 | 52 |
| Pembrolizumab + Paclitaxel + Carboplatin + Avastin + MK-4830 + Docetaxel | Merck | Phase 2 | 52 |
| BMS-986463 | Bristol Myers Squibb | Phase 1 | 32 |
| Mebendazole | Brain Biotech | Phase 1 | 25 |
| Ex-Vivo expanded autologous IL-8 receptor (CXCR2) modified CD70 CAR (8R-70CAR) T cells | Brain Biotech | Phase 1 | 25 |
| APR-246 + Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD) | Aprea Therapeutics | Phase 1/2 | 33 |
Other Products from Aprea Therapeutics
APR-246 + azacitidine + AzacitidinePhase 3
69
APR-246Phase 2
44
APR-246 + Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD)Phase 1/2
33
APR-246 (eprenetapopt) + Acalabrutinib in CLL + APR-246 (eprenetapopt) 4.5 g/d + Venetoclax + Rituximab in CLL + APR-246 (eprenetapopt) 4.5 g/d + (Acalabrutinib, OR, (Venetoclax +Rituximab)), in CLL and/or MCL and/or RT + APR-246 (eprenetapopt) 4.5 g/d + Venetoclax + Rituximab in RTPhase 1/2
33
APR-246 + AzacitidinePhase 1/2
33